Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring
This article was originally published in The Gray Sheet
FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.
You may also be interested in...
CMS’s latest national coverage decision for ventricular assist devices has made it more difficult for non-transplant open-heart surgery facilities to implant ventricular assist devices, but the net business impact of the policy overall has been minimal, according to Thoratec and HeartWare.
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.